Evidence map›Paper›PMID 36389737›Full record

ArticleFrontiers in immunology2022

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells.

Christian Lubich, Katharina Nora Steinitz, Brigitte Hoelbl, Thomas Prenninger, Pauline Maria van Helden, Markus Weiller, Birgit Maria Reipert

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Christian LubichR & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.
Katharina Nora SteinitzR & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.
Brigitte HoelblR & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.
Thomas PrenningerR & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.
Pauline Maria van HeldenR & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.
Markus WeillerR & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.
Birgit Maria ReipertR & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.
Takeda (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Hemophilia A is a severe bleeding disorder caused by the deficiency of functionally active coagulation factor VIII (FVIII). The induction of neutralizing anti-drug antibodies is a major complication in the treatment of hemophilia A patients with FVIII replacement therapies. Why some patients develop neutralizing antibodies (FVIII inhibitors) while others do not is not well understood. Previous studies indicated that the induction of FVIII inhibitors requires cognate interactions between FVIII-specific B cells and FVIII-specific CD4+ T cells in germinal center reactions. In this study, we investigated the FVIII peptide repertoire presented by antigen-presenting cells (APCs) under different microenvironment conditions that are expected to alter the uptake of FVIII by APCs. The aim of this study was to better understand the association between different microenvironment conditions during FVIII uptake and the FVIII peptide patterns presented by APCs. Methods: We used a FVIII-specific CD4+ T cell hybridoma library derived from humanized HLA-DRB1*1501 (human MHC class II) hemophilic mice that were treated with human FVIII. APCs obtained from the same mouse strain were preincubated with FVIII under different conditions which are expected to alter the uptake of FVIII by APCs. Subsequently, these preincubated APCs were used to stimulate the FVIII-specific CD4+ T cell hybridoma library. Stimulation of peptide-specific CD4+ T-cell hybridoma clones was assessed by analyzing the IL-2 release into cell culture supernatants. Results: The results of this study indicate that the specific microenvironment conditions during FVIII uptake by APCs determine the peptide specificities of subsequently activated FVIII-specific CD4+ T cell hybridoma clones. Incubation of APCs with FVIII complexed with von Willebrand Factor, FVIII activated by thrombin or FVIII combined with a blockade of receptors on APCs previously associated with FVIII uptake and clearance, resulted in distinct peptide repertoires of subsequently activated hybridoma clones. Conclusion: Based on our data we conclude that the specific microenvironment during FVIII uptake by APCs determines the FVIII peptide repertoire presented on MHC class II expressed by APCs and the peptide specificity of subsequently activated FVIII-specific CD4+ T cell hybridoma clones.

Indexed as

Hemophilia AHemostaticsAnimalsAntigen-Presenting CellsCD4-Positive T-LymphocytesFactor VIIIHumansMicePeptidesFactor VIIIHemostaticsPeptidesFVIII inhibitorsFVIII presentation by antigen-presenting cellsFVIII-specific CD4+ T-cell hybridoma libraryHemophilia AHLA-DRB1*1501 humanized hemophilic micemicroenvironment during FVIII uptake by antigen-presenting cellsneutralizing anti-drug antibodies

Identifiers

PMID36389737
PMCPMC9645812
OpenAlexW4307691097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.